Scholar Rock is a clinical-stage biopharmaceutical company creating a robust pipeline of therapeutics with the potential to transform the lives of patients suffering from serious diseases, including neuromuscular disorders, cancer, and fibrosis. Our proprietary platform is rooted in our structural biology insights into the activation of latent growth factor precursors and drives the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By exploiting structural differences in the precursor, or latent forms of growth factors, Scholar Rock intends to avoid the historical dose-limiting safety challenges associated with inhibiting the mature form of growth factors for therapeutic effect.
Our first investigational product candidate, apitegromab (SRK-015), is a selective inhibitor of the activation of latent myostatin. We announced positive 12-month top-line data from the TOPAZ trial in April 2021, demonstrating that apitegromab has the potential to improve motor function in patients with Type 2 and Type 3 spinal muscular atrophy (SMA). We anticipate initiating a Phase 3 registrational trial by the end of 2021 and are moving steadfast towards our aim of bringing this potential first muscle-directed therapy to patients with SMA
Our second investigational product candidate, SRK-181, is a selective inhibitor of latent TGFβ1 activation being developed to overcome primary resistance to checkpoint inhibitor therapies (CPIs), such as anti-PD-1 or anti-PD-L1 antibodies. Although CPIs have transformed the cancer treatment landscape, only approximately 20% of patients respond to treatment. We believe SRK-181 has the potential to meaningfully increase the number of patients who can benefit from CPIs. We are evaluating SRK-181 in the ongoing DRAGON Phase 1 proof-of-concept trial (NCT04291079) evaluating patients with locally advanced or metastatic solid tumors. We anticipate initial clinical response and safety data from Part A (dose escalation) portion of the trial by the end of 2021.
We continue to progress our scientific platform and preclinical programs as we apply our structural insights and protein science and antibody expertise to discover antibodies with differentiated therapeutic profiles and develop high-impact medicines for patients suffering from serious diseases.
Summary of Position:
Director-level Senior IP Counsel who will lead the IP strategy for the TGFβ Program, including global prosecution strategy and management of complex patent families. Both US and EP patent attorneys will be considered for this position. The individual will report to the Vice President of IP and work closely with internal and external stakeholders to ensure protection of valuable IP assets for clinical, preclinical and early-stage programs, in a dynamic, multi-functional environment. We seek a highly motivated, highly experienced and business-oriented individual with commitment to excellence, integrity, and passion for making a difference in patients’ lives.
Manage Scholar Rock’s patent portfolio drawn to TGFβ, including preparing US and foreign patent filings and responses to official actions.
Manage and serve as a liaison with outside counsel.
Interact with external stakeholders (e.g., collaborators and licensors).
Work with scientific and clinical teams as well as other functions to understand new developments, and design and implement prosecution strategies to ensure the necessary protection of IP assets and alignment to business goals.
Serve as IP lead on cross-functional program team developing therapeutic assets.
Conduct freedom-to-operate analyses as needed.
Review and evaluate the commercial and technical activities of third parties.
Review technical manuscripts, posters and other materials intended for publication and draft patent applications in response as needed.
Review IP provisions of agreements, including for collaborations, SRAs and MTAs.
8+ years of experience in patent prosecution and IP due diligence and related work in life sciences, of which preferably at least 5+ years spent at a reputable law firm with highly regarded life sciences practice. Prior in-house experience preferred.
Ph.D in biomedical research discipline strongly preferred (e.g., molecular/cellular biology, immunology, biochemistry, neurobiology, etc.). Master’s degree (MS) will be considered for candidates with extensive experience and particularly relevant background.
Registered to practice before the USPTO and good standing in at least one state bar (for US attorney); or, qualified as Chartered Patent Attorney and/or European Patent Attorney (for EP attorney).
Experience in post-grant proceedings and/or litigation preferred.
Experience with transactional matters, including agreement drafting and contract negotiation.
Ability to learn and handle IP-related matters involving a wide variety of therapeutic/diagnostic modalities and disease areas.
Demonstrated ability to multi-task, problem-solve and operate in a fast paced environment, particularly the ability to process complex sets of information and to effectively respond to rapidly changing priorities and deadlines.
Excellent analytical and communication skills.
Strong professionalism and interpersonal skills.
Commitment to accountability, reliability and responsiveness to successfully engage with a cross-functional team.
Scholar Rock is an Equal Opportunity Employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.